[The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SETH)].
The Consensus Document on Alternatives to Allogenic Blood Transfusion (AABT) has been drawn up by a panel of experts from 5 scientific societies. The Spanish Societies of Anesthesiology (SEDAR), Critical Care Medicine and Coronary Units (SEMICYUC), Hematology and Hemotherapy (AEHH), Blood Transfusion (SETS) and Thrombosis and Hemostasis (SETH) have sponsored and participated in this Consensus Document. Alternatives to blood transfusion have been divided into pharmacological and non-pharmacological, with 4 modules and 12 topics. The main objective variable was the reduction of allogenic blood transfusions and/or the number of transfused patients. The extent to which this objective was achieved by each AABT was evaluated using the Delphi method, which classifies the grade of recommendation from A (supported by controlled studies) to E (non-controlled studies and expert opinion). The experts concluded that most of the indications for AABT were based on middle or low grades of recommendation, "C", "D", or "E", thus indicating the need for further controlled studies.
Alberca
Ignacio
I
Asuero
Ma Soledad
MS
Bóveda
José L
JL
Carpio
Nelly
N
Contreras
Enric
E
Fernández-Mondéjar
Enrique
E
Forteza
Alejandro
A
García-Erce
José A
JA
García de Lorenzo
Abelardo
A
Gomar
Carmen
C
Gómez
Aurelio
A
Llau
Juan V
JV
López-Fernández
María F
MF
Moral
Victoria
V
Muñoz
Manuel
M
Páramo
José A
JA
Torrabadella
Pablo
P
Quintana
Manuel
M
Sánchez
Calixto
C
D015119:Aminocaproic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007611:Aprotinin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001802:Blood Substitutes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001804:Blood Transfusion, Autologous; D003102:Colloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077324:Crystalloid Solutions; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D015942:Factor VIIa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006438:Hemodilution; D006470:Hemorrhage / Q000188:drug therapy / Q000628:therapy*; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007552:Isotonic Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D057725:Operative Blood Salvage; D019106:Postoperative Hemorrhage / Q000188:drug therapy; D011292:Premedication; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D001802:Blood Substitutes; D003102:Colloids; D000077324:Crystalloid Solutions; D006397:Hematinics; D006490:Hemostatics; D007552:Isotonic Solutions; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D007611:Aprotinin; C103587:recombinant FVIIa; D007501:Iron; D015942:Factor VIIa; D003894:Deamino Arginine Vasopressin; D015119:Aminocaproic Acid